Related Experiment Video

Updated: Mar 21, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K

Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics

Dickson Adah1, Muzammal Hussain2, Limei Qin3

  • 1State Key Laboratory of Respiratory Disease, Center for Infection and Immunity, Guangzhou Institutes of Biomedicine and Heath, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Science Park, Guangzhou 510530, PR China; University of Chinese, Academy of Sciences, No. 19 Yuquan Road, Beijing 100049, PR China.

Pharmacological Research
|May 10, 2016
PubMed

Insights

Myeloid-derived suppressor cells (MDSCs) drive lung cancer progression and treatment resistance. Targeting MDSCs offers a promising strategy to enhance lung cancer therapies and improve patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Advanced lung cancer remains largely incurable despite current treatments.
  • Tumor-related immune suppression is a key challenge in cancer therapy.
  • Myeloid-derived suppressor cells (MDSCs) play a critical role in tumor immune evasion.

Purpose of the Study:

  • To review the multifaceted roles of MDSCs in the lung tumor microenvironment.
  • To discuss how MDSCs contribute to lung cancer growth, progression, and treatment resistance.
  • To explore the therapeutic potential of targeting MDSCs in lung cancer.

Main Methods:

  • Literature review focusing on myeloid-derived suppressor cells in lung cancer.
  • Analysis of MDSC functions in tumor immune suppression.
  • Evaluation of therapeutic strategies targeting MDSCs.

Main Results:

  • MDSCs promote lung tumor growth and progression by suppressing anti-tumor immunity.
  • MDSC presence is associated with poorer prognosis in lung cancer patients.
  • MDSCs negatively impact the efficacy of chemotherapy and immunotherapy for lung cancer.

Conclusions:

  • Therapeutic targeting of MDSCs can inhibit tumor growth, angiogenesis, and metastasis.
  • Manipulating MDSCs, alone or in combination therapies, may enhance the effectiveness of lung cancer treatments.
Keywords:
AnticancerChemo-immunotherapyLung cancerMDSCsNSCLCSCLC

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K